Explore Vitrafy Life Sciences's Fair Values from the Community and select yours

Vitrafy Life Sciences (ASX:VFY) Full Year 2025 Results

Key Financial Results

• Net loss: AU$32.7m (loss widened by 214% from FY 2024).

We've found 21 US stocks that are forecast to pay a dividend yield of over 6% next year. See the full list for free.

All figures shown in the chart above are for the trailing 12 month (TTM) period

Vitrafy Life Sciences Revenues Disappoint

Revenue missed analyst estimates by 38%.

Looking ahead, revenue is forecast to grow 72% p.a. on average during the next 3 years, compared to a 8.5% growth forecast for the Global Life Sciences industry.

Performance of the market in Australia.

The company's share price is broadly unchanged from a week ago.

Risk Analysis

Be aware that Vitrafy Life Sciences is showing 2 warning signs in our investment analysis that you should know about...

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.